Form 4: Athira Pharma Executive Granted Stock Options and Restricted Stock Units

Mark Worthington, General Counsel and CCO of Athira Pharma, received stock options and restricted stock units on March 3, 2025, according to a Form 4 filing.

Summary

• Mark Worthington, the General Counsel and CCO of Athira Pharma, Inc., was granted stock options and restricted stock units (RSUs) on March 3, 2025.
• The stock options grant covers 85,895 shares with an exercise price of $0.3762 per share, vesting monthly over 48 months starting from the grant date, and expiring on March 2, 2035.
• Additionally, Worthington received 57,263 RSUs, each representing a contingent right to receive one share of Athira Pharma's common stock.
• These RSUs vest 100% on the one-year anniversary of the grant date, contingent upon continued service with the company.
• Following these transactions, Worthington directly owns 85,895 stock options and 57,263 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grants incentivize management, which is generally viewed favorably.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedules encourage continued service and commitment to the company.

Industry Context

Stock options and RSUs are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Athira Pharma.
• Companies such as Biogen, Amgen, and Gilead Sciences also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure retention and performance.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates